solithromycin

Ladenburg Thalmann has downgraded Cempra Inc (NASDAQ: CEMP) to Neutral from Buy following the complete response letter from the FDA for Solithromycin for treatment of Community Acquired Bacterial Pneumonia (CABP). The letter cites both manufacturing deficiencies at contract manufacturer Wockhardt...

Cempra Inc (NASDAQ: CEMP) investors, whose shares had taken a pounding in early November, were waiting for a couple of big catalysts that could drive a rebound this week. The FDA had set two target dates to take action on solithromycin under the PDUFA: On Tuesday, it would make a decision for...

Cempra Inc (NASDAQ: CEMP) has two upcoming catalysts this week, and the company may have too much riding on these, as its stock, which took a pounding in early November, is looking to bounce back. Stock Tanks On FDA's Prelim. Review Cempra stock fell about 61 percent on November 2 after its drug...

Many traders are stepping away from the market in the last week of the year to celebrate the holiday season with friends and family. However, biotech traders know the market never takes a vacation. In fact, there are a number of major biotech catalysts expected out in the near future. Here’s...

Shares of Cempra Inc (NASDAQ: CEMP) plunged 60 percent to a new 52-week low of $7.35 after FDA briefing documents questioned whether solithromycin has some of the same safety risks as Ketek and potential for liver toxicity. The FDA issue came on the heels of company announcing the receipt of a $10...